CRSP Stock — CRISPR Therapeutics AG: Cash, EV, Pipeline

What they do

We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA.

Source: 10-K FY2025 via SEC EDGAR

Share price

$45.63

Market cap

$4,428.1M

Cash

$2,276.6M

Enterprise value

$2,738.5M

Balance sheet

Cash	$2,276.6M
Debt	$586.9M
Net cash	$1,689.6M
Enterprise value	$2,738.5M
Basic shares	97.0M shares
Fully diluted shares	113.4M shares
Fully diluted market cap	$5,176.6M
Cash per share	$23.47
Quarterly burn	$83.5M
Cash runway	27.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common

96.7M

Pre-funded warrants

0.0M

Options

6.9M

RSUs

2.1M

Warrants

0.0M

Converts

7.8M

Conv preferred

0.0M

ESPP reserve

—

FDSO

113.4M

Cap table as of 2026-06-30.

Price history

Loading CRSP daily closes…

Loading price history…

Next catalyst

CTX611 · Est. Nov 11, 2026 · half midpoint · guided Now

Recently reported

CTX310 Phase 1b Positive · 2026-11-09

HDL-C · severe hypertriglyceridemia

Source release →

CTX310 Mixed · 2026-08-28

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 11, 2026 Now half midpoint	CTX611 Phase 2 clinical trial in patients undergoing total knee arthroplasty	Phase 2	patients undergoing total knee arthroplasty	2H 2026
GUIDEDEst. Nov 11, 2026 Now half midpoint	zugo-cel Phase 1 trials in autoimmune disease and Phase 1/2 trial in B-cell malignancies	Phase 1	autoimmune disease and Phase 1/2 trial	2H 2026
Jul 18 - Aug 29 in 8 mo	CTX001	Phase 3	Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance	—
Dec 26, 2027 - Feb 6, 2028 in 14 mo	CTX001	Phase 3	Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn	—
Aug 12 - Sep 23 in 21 mo	CTX340	Phase 2	Hypertension	—
Feb 10 - Mar 24 in 40 mo	CTX112	Phase 2	Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease	—
Feb 12 - Mar 26 in 40 mo	CTX112	Phase 2	B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy	—
Feb 11 - Mar 24 in 64 mo	CTX112	Phase 1	SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis	—
Jan 12 - Feb 23 in 87 mo	CTX112	Phase 2	Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia	—
Nov 11 - Dec 23 in 158 mo	CTX001	Phase 3	Beta-Thalassemia; Thalassemia; Sickle Cell Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CASGEVY

Approved · Active Modality: ex vivo CRISPR/Cas9-edited autologous cell therapy

Aliases exagamglogene autotemcel, exa-cel

Target BCL11A

Partnerships Vertex Pharmaceuticals: joint development and commercialization; Vertex leads and has all decision-making; net profits/losses split 40% CRISPR / 60% Vertex; PRV proceeds sharing ($43M or 42% of net proceeds)

Indications

Sickle cell disease (Approved)
Transfusion-dependent beta thalassemia (Approved)

Status note Approved product; Vertex is the manufacturer and exclusive license holder. Phase 3 pediatric studies CLIMB-151 (SCD ages 5-11) and CLIMB-141 (TDT ages 5-11) ongoing with positive ASH December 2025 data.

Zugocabtagene geleucel

Phase 1 · Active Modality: allogeneic CAR T cell therapy (CRISPR-edited)

Aliases zugo-cel, CTX112

Target CD19

Partnerships Eli Lilly: collaboration and clinical supply agreement to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas

Indications

Relapsed/refractory B-cell malignancies (Phase 1)
Autoimmune diseases (SLE, systemic sclerosis, inflammatory myositis, ITP, warm AIHA) (Phase 1)

Status note Next-generation gene-edited healthy-donor allogeneic CAR T targeting CD19; edits designed to enhance potency, reduce exhaustion, evade immunity. RMAT designation for relapsed/refractory follicular lymphoma and marginal zone lymphoma.

CTX310

Phase 1 · Active Modality: in vivo CRISPR/Cas9 gene editing (LNP-delivered Cas9 mRNA + gRNA)

Target ANGPTL3

Indications

Heterozygous/homozygous familial hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia (Phase 1)

Status note Most advanced in vivo program; Phase 1b prioritizes severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data presented November 2025.

CTX611

Phase 2 · Active Modality: siRNA (long-acting, subcutaneous)

Aliases SRSD107

Target F11 (Factor XI)

Partnerships Sirius Therapeutics: collaboration, option and license agreement (May 2025); 50/50 development cost and profit share; CRISPR leads Phase 3/US commercialization; up to $87.5M milestones

Indications

Thromboembolic disease (VTE prevention in total knee arthroplasty) (Phase 2)

Status note Targets coagulation factor XI mRNA; semi-annual subcutaneous dosing potential. Two Phase 1 trials completed by Sirius.

CTX213

Preclinical · Active Modality: cell therapy (unencapsulated iPSC-derived precursor islet cells, deviceless)

Indications

Type 1 diabetes (Stage not disclosed)

Status note Regenerative medicine program; preclinical efficacy via direct administration. Separate non-exclusive IP license to Vertex for hypoimmune T1D cell therapies (milestones + royalties).

CTX340

Preclinical · Active Modality: in vivo CRISPR/Cas9 gene editing

Target AGT (angiotensinogen)

Indications

Refractory hypertension (Stage not disclosed)

Status note IND-enabling studies ongoing.

CTX460

Preclinical · Active Modality: in vivo gene editing (SyNTase platform)

Target SERPINA1

Indications

Alpha-1 antitrypsin deficiency (Stage not disclosed)

Status note First candidate from proprietary SyNTase editing platform.

CTX321

Preclinical · Active Modality: in vivo CRISPR/Cas9 gene editing

Target LPA

Indications

Elevated lipoprotein(a) (Stage not disclosed)

Status note Next-generation LPA program with updated guide RNA (~2x potency vs CTX320 in preclinical testing); IND-enabling studies ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07758634	Phase 2	Recruiting	Sponsor	CRSP	—	Hypertension	—
NCT07804004	Phase 2	Not yet recruiting	Sponsor	CRSP	—	Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease	—
NCT05643742	Phase 2	Recruiting	Sponsor	CRSP	—	B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy	—
NCT07549698	Phase 2	Recruiting	Sponsor	CRSP	—	Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia	—
NCT07491172	Phase 1	Recruiting	Sponsor	CRSP	—	Cardiovascular; Metabolic Disease; Dyslipidemias	—
NCT06925542	Phase 1	Recruiting	Sponsor	CRSP	—	SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis	—
NCT06208878	Not disclosed	Enrolling by invitation	Sponsor	CRSP	—	Hematologic Malignancy; Solid Malignancy	—
NCT05329649	Phase 3	Active, not recruiting	Collaborator	VRTX	VRTX	Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance	—
NCT05356195	Phase 3	Active, not recruiting	Collaborator	VRTX	VRTX	Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn	—
NCT04208529	Phase 3	Enrolling by invitation	Collaborator	VRTX	VRTX	Beta-Thalassemia; Thalassemia; Sickle Cell Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 10 active trials for CRISPR Therapeutics AG on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
EcoR1 Capital	1,389,276	no change	3.76%	2026-08-14
Logos Global Management	300,000	+300,000	0.70%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CRSP — CRISPR Therapeutics AG ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

CRSP — CRISPR Therapeutics AG